Newron Pharmaceuticals to Present at Key June Investor Conferences

Event summary

  • Newron Pharmaceuticals CEO Stefan Weber and CFO Roberto Galli will participate in the Jefferies Global Healthcare Conference (June 2–4, 2026) and H.C. Wainwright Neuro Perspectives Hybrid Conference (June 15–16, 2026).
  • Corporate presentation at Jefferies scheduled for June 4, 2026, at 2:00 p.m. ET; H.C. Wainwright presentation available on-demand starting June 15, 2026.
  • Evenamide, Newron’s lead compound for treatment-resistant schizophrenia, is in the global pivotal ENIGMA-TRS Phase III development program.
  • Newron has commercialization agreements for evenamide with EA Pharma (Asia) and Myung In Pharm (South Korea).
  • Xadago® (safinamide), Newron’s marketed product for Parkinson’s disease, is commercialized by Zambon (global), Supernus Pharmaceuticals (USA), and Meiji Seika (Japan/Asia).

The big picture

Newron Pharmaceuticals is positioning itself as a key player in neuroscience therapies, with evenamide as its lead candidate for treatment-resistant schizophrenia. The company’s participation in high-profile investor conferences underscores its focus on securing funding and partnerships to advance its pipeline. With Xadago already commercialized, Newron is balancing near-term revenue with long-term development, a strategy that could attract both investors and potential collaborators.

What we're watching

Clinical Progress
The pace at which evenamide advances through the ENIGMA-TRS Phase III program will determine its market potential in treatment-resistant schizophrenia.
Commercial Strategy
How Newron leverages its partnerships with EA Pharma, Myung In Pharm, and others to expand evenamide’s global reach.
Investor Sentiment
Whether the upcoming investor conferences will shift market perception of Newron’s pipeline and commercialization efforts.